Bellwether trials are an important milestone in any multidistrict litigation, and are intended to provide insight into how juries might rule in similar cases included in the proceeding.
New York, New York (PRWEB) June 28, 2015
The parties involved in hundreds of Xarleto lawsuits (http://www.xareltolawsuit2015.com/) that have been consolidated in the U.S. District Court, Eastern District of Louisiana recently discussed a possible schedule for the litigation’s bellwether trials. According to a Minute Entry issued after the Court’s June 22nd Status Conference, four bellwether trials would be convened beginning with the first trial on August 1, 2016, followed by a second trial on August 22, 2016, a third trial on September 12, 2016, and the fourth trial on October 17, 2016. The first two trials would be held in the Eastern District of Louisiana, while the third would take place in the Southern District of Texas, and the fourth in the Southern District of Mississippi. The four bellwether cases would be chosen from a discovery pool that will include 50 Xarelto lawsuits. (In Re: Xarelto Products Liability Litigation, No. 2592)
“Our Firm is representing Xarelto lawsuit plaintiffs in this proceeding, and we are pleased that the Court is moving forward with a bellwether trial plan. Bellwether trials are an important milestone in any multidistrict litigation, and are intended to provide insight into how juries might rule in similar cases included in the proceeding,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is actively filing Xarelto lawsuits in U.S. courts, and continues to evaluate claims on behalf of individuals who allegedly suffered life-threatening internal bleeding and other dangerous complications related to its use.
According to court documents, at least 550 Xarelto lawsuits have been filed in the federal litigation now underway in the Eastern District of Louisiana. The proceeding was established in December 2014 to allow all federally-filed product liability claims involving the drug’s alleged association with uncontrollable bleeding and other serious side effects to undergo coordinated pretrial proceedings. Among other things, plaintiffs allege that the manufacturers of Xarleto wrongly positioned the blood thinner as an improvement over warfarin, an anticoagulant that has been in use for decades. Among other things, the lawsuits point out that unlike Xarelto, internal bleeding associated with warfarin can be reversed with the administration of vitamin K.
According to court documents, Xarelto is a new-generation anticoagulant that was approved by the U.S. Food & Drug Administration in 2011. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.*
Individuals who experienced dangerous internal bleeding and other serious complications allegedly related to the use of Xarelto may be entitled to join this litigation. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.
*accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf, FDA, March 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP